{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006953","form_type":"8-K","ticker":"JYNT","cik":"0001612630","company_name":"JOINT Corp","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.777780+00:00","generated_at":"2026-06-08T06:44:02.332105+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Joint Corp Q3 net loss $716K; plans to refranchise majority of corporate clinics","bullets":["Revenue $29.5M (+11% YoY); net loss $0.05/sh vs income $0.05/sh in Q3 2022.","Operating loss $898K vs operating income $732K; Adj EBITDA $2.9M vs $3.1M.","System-wide sales +8% to $119.3M; comp sales flat; total clinics 914.","Board authorized plan to refranchise/sell majority of corporate-owned clinics.","Reaffirmed FY 2023 guidance: revenue $115-118M, Adj EBITDA $11-12.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006953","json":"https://secwatch.observer/filing/0001171843-23-006953.json","markdown":"https://secwatch.observer/filing/0001171843-23-006953.md","text":"https://secwatch.observer/filing/0001171843-23-006953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1612630/000117184323006953/0001171843-23-006953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1612630/000117184323006953/f8k_091123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:44:02.332105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"547fabf7c8d0ec0b65a219d046edce866c1c32b1","claim":"JOINT Corp reported the quarter ended September 30, 2023 results: revenue $29.5 million, net income net loss of $716,000, or $0.05 per share, EPS $0.05 per share. Guidance reaffirmed.","evidence_excerpt":"of chiropractic clinics, reported its financial results for the quarter ended September 30, 2023. Financial Highlights: Q3 2023 Compared to Q3 2022 ● Grew revenue by 11% to $29.5 million. ● Reported operating loss of $898,000, compared to operating income of $732,000. ● Reported net loss of $716,000, including a loss on disposition or impairment related to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1612630/000117184323006953/0001171843-23-006953-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$29.5 million"},{"label":"Net income","value":"net loss of $716,000, or $0.05 per share"},{"label":"EPS","value":"$0.05 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}